These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 5050300

  • 21. Experimental "in vivo" studies of new antituberculosis drugs: capreomycin, ethambutol, rifampicin.
    Grumbach F.
    Tubercle; 1969 Mar; 50():Suppl:12-21. PubMed ID: 5402543
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [Pulmonary diseases in pregnancy. What drugs are permitted?].
    Stiefelhagen P.
    MMW Fortschr Med; 2009 Mar 05; 151(10):18-9. PubMed ID: 19472660
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Design and study of new agents having antitubercular activity: the original compound perchlosone as a potent agent of etiotropic therapy for tuberculosis].
    Vinogradova TI, Aleksandrova AE, Antonenkova EV, Elokhina VN, Nakhmanovich AS.
    Probl Tuberk; 1999 Mar 05; (3):45-7. PubMed ID: 10420769
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [On the therapy of fibrosis of the lung].
    Zabolay S.
    Z Tuberk Erkr Thoraxorg; 1968 Mar 05; 127(5):291-3. PubMed ID: 5755345
    [No Abstract] [Full Text] [Related]

  • 31. [Prolonged infusion of drugs via the pulmonary artery as a method of treating suppurative processes and pulmonary tuberculosis].
    Chervinskiĭ AA, Kan'shina NF, Tavrovskiĭ VM, Shumskiĭ VG, Gincherman VD.
    Grudn Khir; 1967 Mar 05; 9(2):90-7. PubMed ID: 5603420
    [No Abstract] [Full Text] [Related]

  • 32. [The effect of hyaluronidase on morphologic ractions in experimental tuberculosis].
    Khitrina GV.
    Probl Tuberk; 1971 Mar 05; 49(12):68-74. PubMed ID: 5159692
    [No Abstract] [Full Text] [Related]

  • 33. [Effects of antitubercular drugs on morphological tubercular changes in the lung. I].
    Szymańska D, Chwalibóg B.
    Gruzlica; 1967 Feb 05; 35(2):119-26. PubMed ID: 6045021
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Results with capreomycin in pulmonary tuberculosis.
    Todosijczuk D.
    Ann N Y Acad Sci; 1966 Apr 20; 135(2):1006. PubMed ID: 5327997
    [No Abstract] [Full Text] [Related]

  • 36. [Re-examination of primary treatment].
    Kekkaku; 1968 Mar 20; 43(3):43-5. PubMed ID: 5677407
    [No Abstract] [Full Text] [Related]

  • 37. [Problems of the pathogenic and specific surgical preparation of patients with diffuse forms of pulmonary tuberculosis].
    Repin IuM.
    Probl Tuberk; 1966 Mar 20; 44(4):32-6. PubMed ID: 5997392
    [No Abstract] [Full Text] [Related]

  • 38. [High-titer adrenal cortex extracts as collateral therapy in pulmonary tuberculosis].
    Moreo G, Migliaccio A, Giordano G.
    Clin Ter; 1982 Feb 15; 100(3):249-59. PubMed ID: 7060342
    [No Abstract] [Full Text] [Related]

  • 39. [Retreatment of lung tuberculosis].
    Iwasaki T.
    Naika; 1966 Sep 15; 18(3):487-93. PubMed ID: 5975918
    [No Abstract] [Full Text] [Related]

  • 40. [Blood concentrations and anti-bacterial potency of the blood in relation to secondary antitubercular agents].
    Soejima R, Kaku R, Nagao T, Nozute H.
    Saishin Igaku; 1966 Jan 15; 21(1):62-7. PubMed ID: 5965947
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.